Emerging concepts for the treatment of hepatitis delta

•Several new approaches for treating HDV have entered the clinic.•The entry inhibitor Myrcludex-B shows HDV inhibition in first pilot study.•The first study of the NAP REP2139-Ca reports profound drops in HBsAg and HDV.•The oral prenylation inhibitor lonafarnib inhibits HDV in multiple studies.